How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis

医学 肿瘤科 内科学 肺癌 癌症 食品药品监督管理局 扩展访问 药理学
作者
Alyson Haslam,Timothée Olivier,Vinay Prasad
出处
期刊:International Journal of Cancer [Wiley]
卷期号:156 (12): 2352-2359 被引量:32
标识
DOI:10.1002/ijc.35347
摘要

In 2018, we estimated that eligibility for and response to immune checkpoint inhibitor (ICI) therapies were 44% and 12%, respectively. Since these estimates were published, there have been additional approvals. We sought to provide updated estimates of the percentage of patients with advanced and/or metastatic cancers in the US who are eligible for and respond to immune checkpoint inhibitors (ICIs). Using a cross-sectional analysis (2011-2023) of US Food and Drug Administration approvals (FDA) and deaths reported by the American Cancer Society, we estimated the percentage of patients in the US with advanced or metastatic cancers who are eligible and respond to ICI therapies and the long-term response of ICI drugs. Eleven ICI drugs have been approved for 20 tumor types in the metastatic setting. The estimated eligibility for ICIs increased from 1.54% in 2011 to 56.55% in 2023. The estimated response to ICIs increased from 0.14% in 2011 to 20.13% in 2023. The tumor types with the highest contribution to response and eligibility estimates in 2023 were non-small-cell lung cancer with PD-L1 expression ≤50% and PD-L1 expression >50%. Sixteen drug approvals had long-term progression-free survival (PFS) data available at 3 years follow-up, and 2 had PFS data at 5 years follow-up. Estimated eligibility and response have increased over time, but many people with advanced or metastatic cancers are currently ineligible for ICIs. Only about one-fifth of the patients will respond. Given the wide range of uses, the cost implications of ICIs globally are large.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蔡莹发布了新的文献求助10
刚刚
北海完成签到,获得积分10
1秒前
wanci的应助被下午茶采纳,获得30
1秒前
LZU_Dai完成签到,获得积分10
2秒前
科研通AI65的应助被obito采纳,获得10
2秒前
2秒前
zzx123完成签到,获得积分20
2秒前
ubless607给南楼小阁主的求助进行了留言
3秒前
3秒前
Akim的应助被光电效应采纳,获得10
3秒前
Angleli完成签到,获得积分10
4秒前
dyy123发布了新的文献求助10
4秒前
一一完成签到,获得积分20
4秒前
4秒前
科研通AI6.3的应助被keyanbutong采纳,获得10
4秒前
boom完成签到,获得积分10
5秒前
zhouhuan完成签到 ,获得积分10
5秒前
健壮的大有完成签到,获得积分10
5秒前
烂漫冰烟完成签到,获得积分10
6秒前
7秒前
liu关闭了liu的文献求助
7秒前
yy发布了新的文献求助10
7秒前
8秒前
8秒前
严xixi完成签到 ,获得积分10
9秒前
9秒前
翟思宇发布了新的文献求助10
9秒前
昏睡的衬衫完成签到,获得积分10
10秒前
黑子完成签到,获得积分10
10秒前
聪明依柔完成签到 ,获得积分10
11秒前
12秒前
candiceli发布了新的文献求助20
12秒前
专注寻菱发布了新的文献求助10
12秒前
宋紫馨完成签到 ,获得积分10
13秒前
ali8ba完成签到,获得积分10
13秒前
三岁放火烧山完成签到,获得积分10
13秒前
dyy123完成签到,获得积分10
14秒前
Fayth完成签到,获得积分0
14秒前
江边拔草完成签到,获得积分10
14秒前
七安发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651